TickerSpark Feed

AMGN Coverage

Every TickerSpark article mentioning AMGN — research reports, earnings, trending movements, and macro context.

2 articles

Amgen (AMGN): Growth Broadens Beyond Patent Cliffs

Amgen is growing through patent expirations with broad-based momentum across Repatha, rare disease, oncology, and biosimilars. The stock looks like a Buy, though valuation already reflects much of the resilience.

May 1, 2026·21 min read

Healthcare Drug Manufacturers - General Biotech

Trending StockAMGN

Amgen Inc. (AMGN) drops 5.9% after Q1 earnings beat

Amgen Inc. (AMGN) drops after reporting first-quarter 2026 results, even though the company beat Wall Street on earnings and revenue. Investors appear focused on valuation, growth quality, and whether the quarter was strong enough to justify the stock’s premium.

May 1, 2026·6 min read

Want a deeper dive on AMGN?

Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.

Generate AMGN Report